Fertig, Joanne B.
National Institutes of Health · National Institute on Alcohol Abuse and Alcoholism
6 papers on CoChat
Most cited papers
- Verified
Heterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment
Litten, R. Z., Ryan, M. L., Falk, D. E., Reilly, M., Fertig, J. B., & Koob, G. F. (2015) · Alcoholism: Clinical and Experimental Research
Substance Abuse Treatment and OutcomesAlcohol Consumption and Health Effects
Cited by 330
- Verified
A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine
Substance Abuse Treatment and OutcomesAlcohol Consumption and Health Effects
Cited by 287
- Verified
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials
Falk, D. E., O’Malley, S. S., Witkiewitz, K., Anton, R. F., Litten, R. Z., Slater, M., Kranzler, H. R., Mann, K. F., Hasin, D. S., Johnson, B., et al. (2019) · JAMA Psychiatry
Substance Abuse Treatment and OutcomesAlcohol Consumption and Health Effects
Cited by 120
- Verified
The effects of smoking on acth and cortisol secretion
Seyler, L. E., Fertig, J., Pomerleau, O., Hunt, D., & Parker, K. (1984) · Life Sciences
Stress Responses and CortisolSmoking Behavior and Cessation
Cited by 105
- Verified
Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety
Falk, D. E., Ryan, M. L., Fertig, J. B., Devine, E. G., Cruz, R., Brown, E. S., Burns, H., Salloum, I. M., Newport, D. J., Mendelson, J., et al. (2019) · Alcoholism: Clinical and Experimental Research
Substance Abuse Treatment and OutcomesAlcohol Consumption and Health Effects
Cited by 89
- Verified
A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence
for the National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group, Ryan, M. L., Falk, D. E., Fertig, J. B., Rendenbach-Mueller, B., Katz, D. A., Tracy, K. A., Strain, E. C., Dunn, K. E., Kampman, K., et al. (2017) · Neuropsychopharmacology
Substance Abuse Treatment and OutcomesAlcohol Consumption and Health Effects
Cited by 72
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free